Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 7/20 | 0.45 |
| ▸ | JAK1 | P23458 | 7/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530835 | 0.92 | GPR119 (0.42) | JAK2JAK1OPRM1 | |
| SCHEMBL3523767 | 0.90 | JAK1 (0.45) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL16554255 | 0.90 | MEN1 (0.44) | OPRD1OPRK1JAK2JAK1APP | |
| SCHEMBL4405768 | 0.90 | JAK2 (0.47) | JAK2JAK1OPRM1 | |
| SCHEMBL3526640 | 0.89 | NPC1 (0.44) | TSHRALOX15ATMJAK2JAK1 | |
| SCHEMBL3523742 | 0.88 | TP53 (0.46) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL5916161 | 0.88 | GPR119 (0.45) | TSHRALOX15ATMOPRD1JAK2 | |
| SCHEMBL16565388 | 0.88 | TSHR (0.53) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL2636236 | 0.88 | APP (0.46) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL3526220 | 0.88 | KMT2A (0.43) | TSHRALOX15ATMOPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| EP-1558577-B1 | SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-20060128752-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128752-A1 | Chemical compounds | HTR7, NPSR1, TACR2 | TSHR 40/4885ALOX15 4288/4885ATM 3525/4885 |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | TSHR 2621/4885ALOX15 2649/4885ATM 1089/4885 |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | TSHR 760/4885ALOX15 2690/4885ATM 320/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | TSHR 2621/4885ALOX15 2649/4885ATM 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.